Is there any hope for Parkinson's disease?

Yes, though it helps to be clear about what kind. There is no cure yet, but more than 500 Parkinson's clinical trials are recruiting right now, and researchers are testing treatments from at least six different directions at once. No single drug is guaranteed to work, but the number and variety of approaches in development is larger than it has ever been.

What new Parkinson's treatments are being developed?

Researchers are working on several fronts: smoother forms of dopamine medication such as tavapadon and once-daily infusions, antibodies that clear the alpha-synuclein protein, repurposed diabetes drugs in the GLP-1 class, drugs aimed at genetic forms of Parkinson's (LRRK2 and GBA), stem-cell-based cell replacement, and exercise programs. Some are in late-stage trials, while others are early and unproven.

Is a cure for Parkinson's coming soon?

No one can promise that. A treatment that slows progression is a more realistic near-term goal than a full cure, and even that would need years of trials before approval. Be cautious of any clinic or product that guarantees a cure, because that is a known warning sign.

How many Parkinson's clinical trials are happening right now?

More than 500 Parkinson's clinical trials are actively recruiting worldwide, across dozens of countries and hundreds of research sites. They cover both better symptom control and genuine attempts to slow the disease.

Can exercise slow Parkinson's?

Exercise is the one intervention with strong evidence that families can act on today. Forced-rate cycling, boxing-based programs, treadmill training, and tai chi clearly improve symptoms, function, and quality of life. The evidence that exercise slows progression is encouraging rather than settled, but starting or keeping up regular vigorous exercise is widely recommended.

What the World Is Doing About Parkinson's Disease Right Now

When someone you love is diagnosed with Parkinson's, one of the hardest feelings is helplessness, the sense that there is nothing to be done. That feeling is wrong. Not because a cure is around the corner, it may not be, but because the amount of work happening in Parkinson's research right now is larger than it has ever been. More than 500 clinical trials are actively recruiting, and researchers are coming at the disease from at least six different directions at once. This is a plain-language guide to all of it, written for families.

The Six Ways Researchers Are Attacking Parkinson's

Parkinson's research is not one thing. Researchers are pursuing several different strategies at once, some to slow the disease, some to replace what has been lost, some to protect what remains. You can see all of them with current phases on the drug pipeline tracker.

1. A Smoother Version of the Medication That Already Works

The current standard of care, levodopa, works but imperfectly. Newer treatments deliver dopamine more smoothly: tavapadon (a once-daily pill with its Phase 3 program complete and now submitted to the FDA), foslevodopa/foscarbidopa (Vyalev, a 24-hour infusion approved in 2024), and carbidopa/levodopa extended-release (Crexont, also approved in 2024). Caveat: these improve symptom control, they do not slow the disease.

2. Clearing the Protein That Builds Up in the Brain

Alpha-synuclein is a protein that clumps in the brains of people with Parkinson's. Antibodies like prasinezumab aim to clear it. Neither of prasinezumab's two trials hit its main goal with statistical significance, and an earlier antibody, cinpanemab, failed in 2021. No alpha-synuclein therapy has succeeded in a pivotal trial yet. See disease-modifying vs symptomatic trials.

3. Diabetes Drugs That May Protect the Brain

GLP-1 drugs, the same broad family as Ozempic, may protect nerve cells. The LixiPark trial of lixisenatide enrolled about 156 people for 12 months and found a small but statistically significant slowing of motor decline, alongside common nausea. A closely related drug, exenatide, failed its Phase 3 trial in 2024, so the class is far from proven. See our guide to GLP-1 drugs.

4. Targeting the Genetics of Parkinson's

About 10 to 15 percent of cases have a known genetic component. BIIB122 lowers the activity of the LRRK2 enzyme; its large LUMA trial in early Parkinson's did not slow the disease (reported 2026) and an earlier LRRK2-variant trial was stopped in 2023, though a smaller trial in LRRK2-variant carriers continues. On the GBA side, ambroxol is in a Phase 3 trial, while an earlier drug, venglustat, failed its Phase 2 in GBA-Parkinson's in 2021. Most people with Parkinson's do not carry these mutations.

5. Replacing the Cells That Have Been Lost

Bemdaneprocel uses dopamine neurons grown from stem cells and surgically placed into the brain. A small Phase 1 safety trial was encouraging and a larger controlled trial is planned. Cell transplants have been tried since the 1980s with mixed results, this is early-stage, and it involves brain surgery. Be careful with clinics selling stem cell cures today. See our look at stem cell therapy.

6. Exercise and the Things You Can Do Today

Exercise is the one intervention with strong evidence that families can act on now. Forced-rate cycling, boxing-based programs, treadmill training, and tai chi improve symptoms and quality of life. The evidence that it slows progression is encouraging rather than settled.

The Scale of the Effort

More than 500 Parkinson's trials are recruiting across dozens of countries and hundreds of sites, run by academic centers, drug companies, biotech firms, and government agencies. The full picture is on the research dashboard, and you can browse every recruiting trial or look for studies near where you live.

What This Means for Your Family

If you were recently diagnosed, the treatments in Phase 3 today could reach patients within a few years. If you have lived with Parkinson's for years, newer symptomatic treatments improve quality of life now, and disease-modifying therapies would help everyone. Caregivers can use the caregiver hub for the practical side. No one can promise any single drug will work, but the number and variety of approaches is the reason for hope. The trial matcher takes about a minute.

What You Can Do

Browse the drug pipeline, search trials near you, try the matcher, bring specific trials to your neurologist using our conversation guide, keep exercising, and sign up for the Monday digest.

Frequently Asked Questions

Is there any hope for Parkinson's disease?: Yes, though it helps to be clear about what kind. There is no cure yet, but more than 500 Parkinson's clinical trials are recruiting right now, and researchers are testing treatments from at least six different directions at once. No single drug is guaranteed to work, but the number and variety of approaches in development is larger than it has ever been.
What new Parkinson's treatments are being developed?: Researchers are working on several fronts: smoother forms of dopamine medication such as tavapadon and once-daily infusions, antibodies that clear the alpha-synuclein protein, repurposed diabetes drugs in the GLP-1 class, drugs aimed at genetic forms of Parkinson's (LRRK2 and GBA), stem-cell-based cell replacement, and exercise programs. Some are in late-stage trials, while others are early and unproven.
Is a cure for Parkinson's coming soon?: No one can promise that. A treatment that slows progression is a more realistic near-term goal than a full cure, and even that would need years of trials before approval. Be cautious of any clinic or product that guarantees a cure, because that is a known warning sign.
How many Parkinson's clinical trials are happening right now?: More than 500 Parkinson's clinical trials are actively recruiting worldwide, across dozens of countries and hundreds of research sites. They cover both better symptom control and genuine attempts to slow the disease.
Can exercise slow Parkinson's?: Exercise is the one intervention with strong evidence that families can act on today. Forced-rate cycling, boxing-based programs, treadmill training, and tai chi clearly improve symptoms, function, and quality of life. The evidence that exercise slows progression is encouraging rather than settled, but starting or keeping up regular vigorous exercise is widely recommended.